Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck/Schering: The Next Wave Of Consolidation

This article was originally published in The Pink Sheet Daily

Executive Summary

$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.

You may also be interested in...



Davis To Shepherd Merck & Co. Toward The Post-Keytruda Era, As Frazier Exits

Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.

Merck Folds In Schering-Plough, Begins Job Cuts

Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.

Merck Folds In Schering-Plough, Begins Job Cuts

Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel